Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
Urology
|
April 30, 2013
Epithelial cell adhesion molecule-positive circulating tumor cells as predictive biomarker in patients with prostate cancer
Robert J Amato, Vladislava Melnikova, Yujian Zhang, et al.
Cancer Research
|
December 3, 2005
Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction
Aaron J Berger, Darren W Davis, Carmen Tellez, et al.
Molecular Cancer Therapeutics
|
March 18, 2004
The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo
Ashish M Kamat, Takashi Karashima, Darren W Davis, et al.
Neoplasia (New York, N.Y.)
|
October 26, 2005
The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors
Khalid A Mohamedali, Daniel Kedar, Paul Sweeney, et al.
Cancer Journal (Sudbury, Mass.)
|
February 27, 2003
Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy
Thomas A Buchholz, Darren W Davis, David J McConkey, et al.
Plos One
|
March 28, 2020
EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy
Fanny Le Du, Takeo Fujii, Kumiko Kida, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 6, 2018
Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol
Hope S Rugo, Javier Cortes, Ahmad Awada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2005
Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668
Darren W Davis, Ryan Takamori, Chandrajit P Raut, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2002
Phase I study of recombinant human endostatin in patients with advanced solid tumors
Roy S Herbst, Kenneth R Hess, Hai T Tran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 10, 2004
Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas
John V Heymach, Jayesh Desai, Judith Manola, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
Urology
|
April 30, 2013
Epithelial cell adhesion molecule-positive circulating tumor cells as predictive biomarker in patients with prostate cancer
Robert J Amato, Vladislava Melnikova, Yujian Zhang, et al.
Cancer Research
|
December 3, 2005
Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction
Aaron J Berger, Darren W Davis, Carmen Tellez, et al.
Molecular Cancer Therapeutics
|
March 18, 2004
The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo
Ashish M Kamat, Takashi Karashima, Darren W Davis, et al.
Neoplasia (New York, N.Y.)
|
October 26, 2005
The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors
Khalid A Mohamedali, Daniel Kedar, Paul Sweeney, et al.
Cancer Journal (Sudbury, Mass.)
|
February 27, 2003
Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy
Thomas A Buchholz, Darren W Davis, David J McConkey, et al.
Plos One
|
March 28, 2020
EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy
Fanny Le Du, Takeo Fujii, Kumiko Kida, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 6, 2018
Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol
Hope S Rugo, Javier Cortes, Ahmad Awada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2005
Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668
Darren W Davis, Ryan Takamori, Chandrajit P Raut, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2002
Phase I study of recombinant human endostatin in patients with advanced solid tumors
Roy S Herbst, Kenneth R Hess, Hai T Tran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 10, 2004
Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas
John V Heymach, Jayesh Desai, Judith Manola, et al.
Page
of 3